Intec Pharma — Investor Presentation (September 2019)
27 slides from Intec Pharma's investor presentation, Sep 9, 2019
Slide 1: Corporate Presentation September 2019
Corporate Presentation Nasdaq: NTEC September 2019
Slide 2: Forward-looking statements
This presentation by Intec Pharma Ltd. (referred to as “we” or “our”) contains forward - looking statements about our expectations , beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategi es, plans and pros
Slide 3: Investment Highlights
Investment Highlights 3 Parkinson’s Disease Phase 3 Program AP Cannabinoids (CBD, THC) Various pain indications in Phase 1 Proprietary drug evaluation programs Proprietary oral delivery system of drugs on film The Accordion Pill® (AP) Platform Potential for Multiple External Collaborations Future gr
Slide 4: The Accordion Pill: A new platform for oral drug delivery
The Accordion Pill A new platform for oral drug delivery 4 • AP capsule dissolves and outer layers facilitate unfolding mechanism of films • Layers comprise an inner, controlled release drug - containing layer, and immediate release layer(s) for multiple drug release profiles and/or fixed - dose com
Slide 5: The Accordion Pill (AP) Platform Technology
Each film layer designed as different delivery system; Mix and match multiple layers, multiple drugs 5 Biodegradable polymeric films which combine drugs and inactive ingredients (FDA approved), laminated into planar structure Unique Advantages : – Enhanced gastric retention – Improved PK – High drug
Slide 6: Business Strategy
Business Strategy 6 Partner’s Proprietary Drugs In Development In - house Development Of Existing Drugs 505 (b) 2
Slide 7: Accordion Pill Development Pipeline
Product Candidate Research Phase 1 Phase 2 Phase 3 Status AP - CD/LD For treatment of severe symptoms in advanced Parkinson’s disease Potential partnership for Phase 3 study AP - THC Cannabinoid treatments for various pain indications Reformulating and moving into PK study in 2020 AP - CBD Cannabino
Slide 8: AP-CD/LD Phase III Trial Design
AP - CD/LD Phase III Trial Design ~ 80+ Clinical sites across 10 countries 8 6 Weeks 13 Weeks 2 Weeks 50 / 400 , 50 / 500 BID, TID Open label N= 462 Double Blind 12 Months 6 Weeks Stabilization on Sinemet® AP - CD/LD Conversion Enrollment Committee Review Treatment Period Sinemet + AP - CD/LD dummy
Slide 9: Phase 3 ACCORDANCE Study Results
AP CD/LD was numerically superior in improving OFF time but not statistically superior • Provided treatment for PD symptoms but did not demonstrate a statistically significant reduction in OFF time compared with IR - CD/LD under conditions established in the protocol • Waking OFF time (first hour) c
Slide 10: Phase 3 ACCORDANCE Study Take Aways
Phase 3 ACCORDANCE Study Take Aways 10 Validated the Accordion Pill platform x Delivered levodopa and treated PD symptoms x Provided long - term safety data • Sub - optimal dosing – AP dose was capped at AP - CD/LD 50 / 500 mg TID; IR - CD/LD had no limit to daily doses – 1.6 to 2.0 ratio of AP - CD
Slide 11: Primary Analysis - Average Hours of OFF Time Daily
3.5 4.0 4.5 5.0 5.5 6.0 6.5 0 5 10 15 20 25 Mean Daily OFF Time (Hours) Time (Weeks) Primary Analysis - Average Hours of “OFF” Time Daily 11 AP IR Sinemet Titration AP Titration Double Blind Maintenance
Slide 12: Post Hoc Analysis - Patients Not Requiring Maximal AP Dose
3.5 4.0 4.5 5.0 5.5 6.0 6.5 0 5 10 15 20 25 Mean Daily OFF Time (Hours) Time (Weeks) Post Hoc Analysis - All Patients NOT Requiring The Maximal AP Dose of 1500 mg LD 12 AP IR Sinemet Titration AP Titration Double Blind Maintenance
Slide 13: Post Hoc Analysis - 1.6 to 2.0 Dose Ratio Patients
3.5 4.0 4.5 5.0 5.5 6.0 6.5 0 5 10 15 20 25 Mean Daily OFF Time (Hours) Time (Weeks) Post Hoc Analysis - Patients Who Received 1.6 to 2.0 Dose Ratio of AP LD to IR LD 13 AP IR Sinemet Titration AP Titration Double Blind Maintenance
Slide 14: Pre-Commercial Activities
Pre - Commercial Activities 14 Regulatory Market Access Rx Packaging Manufacturing Market Research
Slide 15: Commercial Scale Manufacturing
Commercial Scale Manufacturing • Partnership with LTS for commercial scale production of AP - CD/LD • Leading global formulation and film technology manufacturer • Commercial scale machine delivered in YE 18 • Qualification of AP commercial manufacturing system in 3 Q 19 • Validation, bridging and s
Slide 16: Partnering PD Program for Late Stage Development and Commercialization
Partnering PD Program for Late Stage Development and Commercialization 16 The Opportunity • ACCORDANCE results validate the AP platform and provide long - term safety data • Responder analysis and subset analyses provide key insights for future study design and dosing • Commercial scale manufacturin
Slide 17: Cannabis and Pain Relief
Cannabis and Pain Relief 17 • Medical cannabis market has growing acceptance and regulatory path forward • Pain relief is most commonly cited reason for medical use of cannabis • Endocannabinoid system is associated with mechanisms of pain reduction Challenges : • Hydrophobic • Insoluble • Poorly bi
Slide 18: Phase I Topline Results with AP-CBD/THC
Single - center, single - dose, randomized, 3 - way crossover study compared PK, safety and tolerability of AP - CBD/THC with Sativex ® in 21 normal healthy volunteers Phase I Topline Results with AP - CBD/THC 18 • Accordion Pill delivered CBD and THC with significant improvements in exposure compar
Slide 19: Accordion Pill CBD and THC Next Steps
Accordion Pill CBD and THC Next Steps 19 • Evaluate THC alone and CBD alone for pain states • Reformulation of AP - THC following initial PK study results • Phase 1 PK study of AP - THC planned for 2020 Exploring the individual components will provide additional indications to pursue potential indic
Slide 20: Partners' Proprietary Drugs in Development
Partners’ Proprietary Drugs in Development 20 20 • Explore using the Accordion Pill platform for a proprietary Novartis compound • Developing Accordion Pill to meet Novartis criteria x Achieved technical specifications in vitro (YE 18 ) x Conducted Phase 1 PK study ( 1 H 19 ) x Phase 1 PK data to No
Slide 21: Accordion Pill with Poorly Soluble Drugs: PK Clinical Study
Potential for Enhancing Delivery and Retention 21 • Many drugs fail to reach the market due to poor bioavailability • ~ 40 % of top 200 major market drugs are poorly soluble (BCS Class II or Class IV ( 1 ) ) • Historically, ~ 90 % of new chemical entities in development, were either BCS Class II or
Slide 22: IP Overview: Four Layers of IP Protection
IP Overview 22 • Platform IP – Various Accordion Pill dosage forms – Latest U.S. patent expires in 2029 • Manufacturing IP – Methods for making/folding gastro - retentive drug delivery system – U.S. patent expires in 2028 • Specific formulation IP – For example, U.S. patent of AP - CD/LD expires in
Slide 23: Capital Structure and Cash Position
Capital Structure and Cash Position 23 ~ 33 M Ordinary Shares Outstanding Capital Structure Cash $~ 22 M In cash and cash equivalents and financial assets as of 6/30/19 (unaudited) $~ 8 - 10 M Quarterly Cash Burn • No debt • No warrants • No preferred stock • No convertibles
Slide 24: Experienced Board of Directors
Experienced Board of Directors 24 John W. Kozarich, Ph.D. Chairman Gil Bianco Director Hila Karah Director Anthony J. Maddaluna Director Roger J. Pomerantz, M.D. Director Isaac Silberman Director Sulam Financial Holdings Company W. Brad Hayes Director
Slide 25: Accomplishments and Milestones
Accomplishments and Milestones 25 Recent Upcoming x Completed qualification studies of commercial manufacturing with LTS x Reported top - line data from Phase 3 study of AP - CD/LD in Parkinson’s disease did not meet primary endpoint x Completed PK studies for Novartis’ proprietary AP x Expanded pip
Slide 26: Investment Highlights
Investment Highlights 26 Parkinson’s Disease Phase 3 Program AP Cannabinoids (CBD, THC) Various pain indications in Phase 1 Proprietary drug evaluation programs Proprietary oral delivery system of drugs on film The Accordion Pill® (AP) Platform Potential for Multiple External Collaborations Future g
Slide 27: Thank you
Thank you www.intecpharma.com
Intec Pharma — Investor Presentation (September 2019) on 6ix